Detalhe da pesquisa
1.
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Cancer Immunol Immunother
; 70(10): 2911-2924, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33693963
2.
Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients - a single centre cohort study.
Transpl Int
; 33(4): 402-413, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31908055
3.
How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Transfusion
; 58(6): 1340-1347, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29542132
4.
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells.
Front Immunol
; 14: 1187665, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37928520
5.
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Front Immunol
; 13: 953849, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35990652
6.
Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.
Biomedicines
; 10(3)2022 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35327433
7.
Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
Front Immunol
; 12: 797209, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087522
8.
Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy.
Cancers (Basel)
; 13(3)2021 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33540698
9.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Blood Cancer J
; 11(8): 146, 2021 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392311
10.
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Clin Lymphoma Myeloma Leuk
; 21(5): 328-337.e1, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33610500
11.
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Front Immunol
; 10: 2361, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31649672
12.
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Sci Rep
; 9(1): 18630, 2019 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31819100
13.
Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Antioxidants (Basel)
; 8(11)2019 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31652983
14.
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Clin Cancer Res
; 23(19): 5824-5835, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28659311
15.
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Leuk Lymphoma
; 63(8): 1970-1974, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35369829
16.
Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.
Oncoimmunology
; 5(12): e1250051, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28123890
17.
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
PLoS One
; 6(11): e27299, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22073309
18.
Visfatin/Nampt induces telomere damage and senescence in human endothelial cells.
Int J Cardiol
; 175(3): 573-5, 2014 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24874905